Development and Validation of Hub Genes for Adrenal Aldosterone-Producing Adenoma by Integrated Bioinformatics Analysis

References

• Rossi GP. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol. 2011;7(8):485–495. doi:10.1038/nrendo.2011.76
   PubMed Web of Science ®Google Scholar
• Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–1916. doi:10.1210/jc.2015-4061
   PubMed Web of Science ®Google Scholar
• Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039–1045. doi:10.1161/01.HYP.27.5.1039
   PubMed Web of Science ®Google Scholar
• Yang Q, Wang R, Wei B, et al. Candidate biomarkers and molecular mechanism investigation for glioblastoma multiforme utilizing WGCNA. Biomed Res Int. 2018;2018:4246703. doi:10.1155/2018/4246703
   PubMed Web of Science ®Google Scholar
• Yin L, Cai Z, Zhu B, Xu C. Identification of key pathways and genes in the dynamic progression of HCC based on WGCNA. Genes. 2018;9(2):92. doi:10.3390/genes9020092
   PubMed Web of Science ®Google Scholar
• Di Y, Chen D, Yu W, Yan L. Bladder cancer stage-associated hub genes revealed by WGCNA coexpression network analysis. Hereditas. 2019;156:7. doi:10.1186/s41065-019-0083-y
   PubMed Web of Science ®Google Scholar
• Tang J, Kong D, Qiuxia C, et al. Prognostic genes of breast cancer identified by gene co-expression network analysis. Front Oncol. 2018;8:374. doi:10.3389/fonc.2018.00374
   PubMed Web of Science ®Google Scholar
• Xia WX, Yu Q, Li G-H, et al. Identification of four hub genes associated with adrenocortical carcinoma progression by WGCNA. PeerJ. 2019;7:e6555. doi:10.7717/peerj.6555
   PubMed Web of Science ®Google Scholar
• Murakami M, Yoshimoto T, Nakabayashi K, et al. Integration of transcriptome and methylome analysis of aldosterone-producing adenomas. Eur J Endocrinol. 2015;173(2):185–195. PMID: 25953827. doi:10.1530/EJE-15-0148
   PubMed Web of Science ®Google Scholar
• Ye P, Mariniello B, Mantero F, et al. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol. 2007;195(1):39–48. PMID: 17911395. doi:10.1677/JOE-07-0037
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res. 2009;15(2):668–676. PMID: 19147773. doi:10.1158/1078-0432.CCR-08-1067
   PubMed Web of Science ®Google Scholar
• Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol. 2012;181(3):1017–1033. PMID: 22800756. doi:10.1016/j.ajpath.2012.05.026
   PubMed Web of Science ®Google Scholar
• Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004;22:863–869. doi:10.1097/00004872-200405000-00001
   PubMed Web of Science ®Google Scholar
• Kanarek-Kucner J, Stefański A, Barraclough R, et al. Insufficiency of the zona glomerulosa of the adrenal cortex and progressive kidney insufficiency following unilateral adrenalectomy - case report and discussion. Blood Press. 2018;27(5):304–312. doi:10.1080/08037051.2018.1470460
   PubMed Web of Science ®Google Scholar
• Tajbakhsh A, Pasdar A, Rezaee M, et al. The current status and perspectives regarding the clinical implication of intracellular calcium in breast cancer. J Cell Physiol. 2018;233(8):5623–5641. doi:10.1002/jcp.26277
   PubMed Web of Science ®Google Scholar
• Prevarskaya N, Skryma R, Shuba Y. Ion channels and the hallmarks of cancer. T Rends Mol Med. 2010;16:107–121. doi:10.1016/j.molmed.2010.01.005
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(5):7–70. doi:10.1016/S0092-8674(00)81683-9
   Web of Science ®Google Scholar
• Bose T, Cieślar-Pobuda A, Wiechec E, et al. Role of ion channels in regulating Ca2+homeostasis during the interplay between immune and cancer cells. Cell Death Dis. 2015;6(2):e1648. doi:10.1038/cddis.2015.23
   PubMed Web of Science ®Google Scholar
• Felizola SJA, Nakamura Y, Satoh F, et al. Glutamate receptors and the regulation of steroidogenesis in the human adrenal gland: the metabotropic pathway. Mol Cell Endocrinol. 2014;382(1):170–177. doi:10.1016/j.mce.2013.09.025
   PubMed Web of Science ®Google Scholar
• Itcho K, Oki K, Kobuke K, et al. Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma.Mol. Cell Endocrinol. 2018;461:100–104. doi:10.1016/j.mce.2017.08.019
   PubMed Web of Science ®Google Scholar
• Zhao N, Peacock SO, Lo CH, et al. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Sci Transl Med. 2019;11:498. doi:10.1126/scitranslmed.aaw4636
   Web of Science ®Google Scholar
• Fenner A. AVPR1A: a target in CRPC? Nat Rev Urol. 2019;16(9):508. doi:10.1038/s41585-019-0218-y
   PubMed Web of Science ®Google Scholar
• Akiyama K, Ohga N, Maishi N, et al. The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma. Pathol Int. 2013;63(1):37–44. doi:10.1111/pin.12031
   PubMed Web of Science ®Google Scholar
• Stockwin LH, Vistica DT, Kenney S, et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer. 2009;9. doi:10.1186/1471-2407-9-22
   Web of Science ®Google Scholar
• Ye J, Ren Y, Chen J, et al. Prognostic significance of preoperative and postoperative complement C3 depletion in gastric cancer: a three-year survival investigation. Biomed Res Int. 2017:2017. doi:10.1155/2017/2161840
   Web of Science ®Google Scholar
• Vogt PK. Jun, the oncoprotein. Oncogene. 2001;20(19):2365–2377. doi:10.1038/sj.onc.1204443
   PubMed Web of Science ®Google Scholar
• Vleugel MM, Greijer AE, Bos R, et al. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol. 2006;37(6):668–674. doi:10.1016/j.humpath.2006.01.022
   PubMed Web of Science ®Google Scholar
• Oya M, Mikami S, Mizuno R, et al. C-Jun activation in acquired cystic kidney disease and renal cell carcinoma. J Urol. 2005;174(2):726–730. doi:10.1097/01.ju.0000164656.99251.77
   PubMed Web of Science ®Google Scholar
• Eckhoff K, Flurschütz R, Trillsch F, et al. The prognostic significance of Jun transcription factors in ovarian cancer. J Cancer Res Clin Oncol. 2013;139(10):1673–1680. doi:10.1007/s00432-013-1489-y
   PubMed Web of Science ®Google Scholar
• Zalloua PA, Azar ST, Delépine M, et al. WFS1 mutations are frequent monogenic causes of juvenile-onset diabetes mellitus in Lebanon. Hum Mol Genet. 2008;17(24). doi:10.1093/hmg/ddn304
   PubMed Web of Science ®Google Scholar
• Sharaf SA, Kantoush NA, Ayoub DF, et al. Altered expression of WFS1 and NOTCH2 genes associated with diabetic nephropathy in T2DM patients. Diabetes Res Clin Pract. 2018:140. doi:10.1016/j.diabres.2018.03.053
   Web of Science ®Google Scholar
• Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43:435–449. doi:10.1016/j.immuni.2015.09.001
   PubMed Web of Science ®Google Scholar
• Weiss RH. Metabolomics and metabolic reprogramming in kidney cancer. Semin Nephrol. 2018;38:175–182. doi:10.1016/j.semnephrol.2018.01.006
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–221. doi:10.3322/caac.20078
   PubMed Web of Science ®Google Scholar